Kevin Flanigan
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications. (NCT04179409) | Kevin Flanigan | 2020-02-18 |
| Spironolactone Versus Prednisolone in DMD (NCT03777319) | Kevin Flanigan | 2018-12-05 |
| Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy (NCT03333590) | Kevin Flanigan | 2017-11-06 |
Track Kevin Flanigan automatically
Every clearance here is in the API, with alerts when new ones post.